Nurix Therapeutics, Inc.
NRIX evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for NRIX—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · NRIX
Nurix Therapeutics is a clinical-stage biopharmaceutical company focused on developing targeted protein degradation drugs, with lead candidates in oncology and inflammation, and a cash position of $68.7M as of 2026-05-31.
Key risk: No approved products
BioSniper Score
Based on 6 of 6 signals
Market Cap
$2.72B
Cash Runway
5.7 moLead Asset
bexobrutideg (Phase 3)Next Catalyst
Phase3_Topline · Jun 1, 2032Financial data as of May 31, 2026.
Tracking 2 pipeline candidates · 9 clinical trials · 1 catalyst for Nurix Therapeutics, Inc..
Nurix Therapeutics is a clinical-stage biopharmaceutical company focused on developing targeted protein degradation drugs, with lead candidates in oncology and inflammation, and a cash position of $68.7M as of 2026-05-31.
- Lead candidate NX-5948 (bexobrutideg) has received Fast Track Designation from the FDA for two indications and PRIME designation from the EMA for chronic lymphocytic leukemia [sec · filed 2025-03-28].
- Cash and equivalents were $68.7M as of 2026-05-31, with a net loss of $89.5M for the same period [sec].
- The company has no approved products and has not generated revenue from product sales [sec_mda · as of 2026-04-08].
- Nurix is advancing a pipeline including bexobrutideg (Phase 1/2), zelebrudomide (Phase 1), and NX-1607 (Phase 1) [sec_mda · as of 2026-07-09].
- The company has expanded its discovery platform to include AI-powered drug discovery [sec · filed 2025-03-28].
What works
- NX-5948 has received Fast Track Designation from the FDA for two indications and PRIME designation from the EMA for chronic lymphocytic leukemia, which may accelerate development and review [sec · filed 2025-03-28].
- The company has a diversified pipeline with multiple wholly owned programs in oncology and inflammation/immunology, reducing single-asset risk [sec · filed 2025-03-28].
- Nurix has expanded its discovery platform to include AI-powered drug discovery, leveraging early investments in E3 ligase research and DNA-encoded libraries [sec · filed 2025-03-28].
What to weigh
- The company has no approved products and has not generated any revenue from product sales, relying entirely on external funding [sec_mda · as of 2026-04-08].
- Cash and equivalents of $68.7M as of 2026-05-31 may be insufficient to fund operations beyond the next 12 months without additional capital [sec_mda · as of 2026-07-09].
- The company has a history of significant net losses, with a net loss of $89.5M for the period ending 2026-05-31 [sec].
- All drug candidates are in early-stage clinical trials (Phase 1 or Phase 2), with no guarantee of eventual regulatory approval or commercial success [sec_mda · as of 2026-07-09].
From the filings
Quoted directly from source documents.
NX-5948 has received Fast Track Designation from the FDA for two indications and PRIME designation from the EMA for chronic lymphocytic leukemia.
“Receiving Fast Track Designation from the U.S. Food and Drug Administration for NX-5948 for two indications as well as PRIME designation for NX-5948 for chronic lymphocytic leukemia from the European Medicines Agency.”
SEC filings · March 28, 2025
The company has no approved products and has not generated any revenue from product sales.
“We do not have any products approved for sale, and we have not generated any revenue from product sales.”
SEC MD&A · April 8, 2026
The company is advancing bexobrutideg through Phase 1 and Phase 2 clinical trials.
“the progress, costs and results of our Phase 1 and Phase 2 clinical trials for our lead drug candidate bexobrutideg”
SEC MD&A · July 9, 2026
Catalyst timeline
- 2032-06-01 · Phase3_Topline · nx-5948 — Phase 3 Topline: A Phase 3, Randomized, Open-label, Multicenter Study of NX-5948 Versus Pirtobrutinib in Relapsed/Ref — Topline results from the Phase 3 trial comparing NX-5948 to pirtobrutinib in relapsed/refractory CLL will be a key efficacy and safety readout.
Risks & what to watch (4)›
Key risks
- No approved products — The company has no products approved for sale and no revenue from product sales, relying entirely on external funding [sec_mda · as of 2026-04-08].
- Cash runway uncertainty — Cash of $68.7M as of 2026-05-31 may not sustain operations beyond 12 months without additional capital [sec_mda · as of 2026-07-09].
- Early-stage pipeline — All drug candidates are in Phase 1 or Phase 2 trials, with no guarantee of regulatory approval or commercial success [sec_mda · as of 2026-07-09].
- Significant net losses — Net loss of $89.5M for the period ending 2026-05-31, indicating ongoing high cash burn [sec].
What to watch
- Phase 3 topline data for NX-5948 versus pirtobrutinib in relapsed/refractory CLL, expected around 2032-06-01 [upcoming catalysts].
- Progress of Phase 1/2 trials for bexobrutideg (NX-5948) and Phase 1 trials for zelebrudomide and NX-1607 [sec_mda · as of 2026-07-09].
- Receipt of $700.0M upfront payment from Roche in the third fiscal quarter of 2026, which could extend cash runway [sec_mda · as of 2026-07-09].
- Any additional collaboration, licensing, or equity financing announcements to address funding needs beyond 12 months [sec_mda · as of 2026-07-09].
Sources: SEC filings · SEC MD&A · Generated August 29, 2026 · How we verify sources →
Run Nurix Therapeutics, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Nurix Therapeutics, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 6 of 6 signals · derived from public data
5.7 months
D/E 0.33 · 0% dilution
Lead: Phase 3
2 candidates
1 upcoming, next in ~2102d
0 buys · 21 sells (180d)
Runway
Catalysts
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
194
Total value held
$1.68B
| Holder | Shares | Value |
|---|---|---|
| blackrock, inc. | 8,925,642 | $138.3M |
| vanguard capital management llc | 8,854,224 | $137.2M |
| perceptive advisors llc | 7,421,754 | $115.0M |
| deep track capital, lp | 6,345,244 | $98.4M |
| fmr llc | 5,541,271 | $85.9M |
| state street corp | 5,141,195 | $79.7M |
| morgan stanley | 4,931,999 | $76.4M |
| baker bros. advisors lp | 4,658,556 | $72.2M |
| general atlantic, l.p. | 4,101,865 | $63.6M |
| pictet asset management holding sa | 2,726,138 | $42.3M |
Showing top 10 of 194 institutional holders of Nurix Therapeutics, Inc.. Open the full 13F history after sign-in.
Short Interest
as of Apr 28, 2026- % of float
- 18.8%
- Days to cover
- 12.9
- Shares short
- 19,201,724
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
NRIX short interestGovernance
Frequently asked questions
What is the AI investment thesis for Nurix Therapeutics, Inc.?
Nurix Therapeutics is a clinical-stage biopharmaceutical company focused on developing targeted protein degradation drugs, with lead candidates in oncology and inflammation, and a cash position of $68.7M as of 2026-05-31.
What is Nurix Therapeutics, Inc.'s lead drug candidate?
Nurix Therapeutics, Inc.'s most advanced tracked candidate is bexobrutideg (Phase 3) for Treatment of relapsed or refractory B-cell malignancies; being explored for autoimmune and inflammatory diseases. Phase 2 study in patients with relapsed or refractory CLL who failed three previous lines of therapy. Fast Track designation in CLL/SLL and WM..
What is Nurix Therapeutics, Inc.'s next catalyst?
Nurix Therapeutics, Inc.'s next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: A Phase 3, Randomized, Open-label, Multicenter Study of NX-5948 Versus Pirtobrutinib in Relapsed/Ref" — expected June 1, 2032.
Who is the CEO of Nurix Therapeutics, Inc.?
Dr. Arthur T. Sands M.D., Ph.D. is the chief executive officer of Nurix Therapeutics, Inc. (NRIX).
Where is Nurix Therapeutics, Inc. headquartered?
Nurix Therapeutics, Inc. (NRIX) is headquartered in Brisbane, CA, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.